afatinib
-
January 16, 2018
Targetable Mutations in NSCLC: More Testing Needed!
Emma Shtivelman, PhDDiagnosis of adenocarcinoma of the lung, a major subtype of non-small lung cancer (NSCLC), nowadays triggers mandatory testing of tumor tissue for alterations in four genes: EGFR, ALK, ROS1, and more recently, BRAF. If present, these alterations predict sensitivity to specific targeted drugs approved by the U.S. Food and Drug Administration (FDA) that work better and often longer than standard chemotherapy, and are better… Read more »
-
September 5, 2017
EGFR-mutant NSCLC: Choice of First-Line Treatment May Get More Complicated
Emma Shtivelman, PhDMedical guidelines for treatment of newly diagnosed non-small cell lung cancer (NSCLC) mandate upfront testing of tumor tissue for mutations in the EGFR gene (as well as ALK and ROS gene translocation). EGFR mutations are found in 10 to 15% of white patients, but in patients of East Asian origin such mutations are in encountered in approximately 48%. However, with new data and drugs… Read more »
-
June 16, 2016
Lung Cancer Highlights from ASCO 2016
Emma Shtivelman, PhDThis year, the Annual Meeting of the American Society of Clinical Oncology (ASCO) did not produce any truly groundbreaking revelations about new treatments for lung cancer. However, researchers did report quite a few positive findings, and some disappointing ones.